ACCESS-AP: A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04743323
Collaborator
United States Department of Defense (U.S. Fed), University of Pittsburgh (Other), Alcohol Research Group (Other), Ohio State University (Other), VA Greater Los Angeles Healthcare System (U.S. Fed)
160
4
48
40
0.8

Study Details

Study Description

Brief Summary

The Purpose of this study is to investigate changes in alcohol consumption in the period leading up to the onset of pancreatitis and compare that to levels of drinking during asymptomatic periods.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    There is no question that long-term heavy consumption of alcohol leads to increased risk of recurrent acute and chronic pancreatitis. While many patients and providers assume that heavy episodic alcohol consumption leads to acute pancreatitis, it is yet unknown whether 'binge' drinking truly causes pancreatitis and if so, what the relevant timing and duration of hazardous alcohol consumption is. Because of the lack of clarity on the transient effects of alcohol on acute pancreatitis, patients and providers are left with an uncertain disease progression and lack of tailored alcohol reduction recommendations.

    Our study aims to investigate changes in alcohol consumption in the period leading up to the onset of pancreatitis and compare that to levels of drinking during asymptomatic periods. This epidemiologic design is called the case-crossover study, in which the diseased person serves as his/her own control. This study design has advantages over typical case-control studies in that factors that do not change within the individual, such as sex, race, genetic risks, will not interfere with evaluating the causal role of heavy episodic drinking on pancreatitis.

    Participants in this study will undergo detailed interview on recent and lifetime alcohol consumption and other correlated health behaviors while they are hospitalized. Blood and urine will be collected during the hospitalization. After discharge, they will be interviewed again for any changes in alcohol consumption and blood and urine will be collected during a standard of care visit. The investigators will chart the progression of their disease through quarterly check-up by phone and through the medical records.

    Ultimately, the investigators aim to generate data that will empower patients and providers to develop tailored regimens for prevention of recurrent acute pancreatitis, that will have lasting beneficial effects in averting irreversible damage to the pancreas.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    160 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease
    Actual Study Start Date :
    Jun 1, 2020
    Anticipated Primary Completion Date :
    Jul 1, 2023
    Anticipated Study Completion Date :
    Jun 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Study Participants

    Participants will be recruited whilst hospitalized for an acute episode of pancreatitis. They will be interviewed about their health behaviors including alcohol consumption during the two weeks immediately preceding the onset of pancreatitis. Blood and urine bio-specimens will be collected at this time. Following discharge from hospital (5-26 weeks) the same participant will be interviewed again during an asymptomatic control period and blood and urine bio-specimens will be collected. This study will compare the participant's exposure immediately preceding the onset of pancreatitis to that of an asymptomatic control period from the same participant. Participants will be followed for 24 months via review of their medical records every 6 months to assess any recurrent disease or progression of disease.

    Outcome Measures

    Primary Outcome Measures

    1. Alcohol Consumption [Between 5-26 weeks]

      Compare alcohol consumption prior to an attack of Acute Pancreatitis to that during an asymptomatic control period. Alcohol consumption will be measured by a 48-hour recall questionnaire, and timeline follow-back instrument.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Aged 18-75 years at the time of eligibility assessment

    • Currently hospitalized with Acute Pancreatitis (AP) per Revised Atlanta

    Classification, which requires two of the following evidence of pancreatitis:
    1. Abdominal pain consistent with AP (acute onset of a persistent, severe, epigastric pain often radiating to the back)

    2. Serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal

    3. Characteristic findings of AP on computed tomography (CT), magnetic resonance imaging (MRI) or transabdominal ultrasonography

    • Alcohol Use Disorders Identification Test Consumption (AUDIT-C) alcohol consumption score of ≥3
    Exclusion Criteria:
    • Pancreatitis presumed to be related to: gallstones, medication, trauma, autoimmune pancreatitis, post-ERCP pancreatitis, pancreatic ductal adenocarcinoma, suspected cystic neoplasm, neuroendocrine tumors, and other uncommon tumors.

    • Chronic pancreatitis with calcification(s).

    • Pancreatic cancer or pancreatic metastasis from other malignancies.

    • History of pancreas transplant or pancreatectomy

    • Current medical or psychiatric illnesses that in the investigator's opinion would compromise their ability to tolerate study procedures or participate in longitudinal follow up.

    • Currently incarcerated.

    • Known current pregnancy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cedars-Sinai Medical Center Los Angeles California United States 90034
    2 Veterans Affairs Greater Los Angeles Healthcare System Los Angeles California United States 90034
    3 Ohio State University Columbus Ohio United States 43210
    4 University of Pittsburg Pittsburgh Pennsylvania United States 15260

    Sponsors and Collaborators

    • Cedars-Sinai Medical Center
    • United States Department of Defense
    • University of Pittsburgh
    • Alcohol Research Group
    • Ohio State University
    • VA Greater Los Angeles Healthcare System

    Investigators

    • Principal Investigator: Christie Y Jeon, ScD, Cedars-Sinai Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Christie Jeon, Research Scientist, Cedars-Sinai Medical Center
    ClinicalTrials.gov Identifier:
    NCT04743323
    Other Study ID Numbers:
    • STUDY00000364
    • 7W81XWH1910888
    First Posted:
    Feb 8, 2021
    Last Update Posted:
    Feb 18, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 18, 2021